Efficacy and safety of antioxidant treatment with α-lipoic acid over 4 years in diabetic polyneuropathy
from Diabetes Care (subscriber only)
In a multicenter randomized double-blind parallel-group trial, 460 diabetic patients with mild-to-moderate DSPN were randomly assigned to oral treatment with 600 mg ALA once daily (n = 233) or placebo (n = 227) for 4 years. Primary end point was a composite score (Neuropathy Impairment Score [NIS]–Lower Limbs [NIS-LL] and seven neurophysiologic tests). Secondary outcome measures included NIS, NIS-LL, nerve conduction, and quantitative sensory tests (QSTs).
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063